NewSquare Capital’s ANI Pharmaceuticals ANIP Stock Holding History

NewSquare Capital’s Portfolio ANIP Stock Details ANIP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-38	Closed	-$3K	–	330
2016 Q3	$3K	Buy	+38	New	+$2.38K	﹤0.01%	376

Other funds holding ANIP

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Glenmede Trust Philadelphia, Pennsylvania $22.7B AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Nomura Holdings Tokyo, Japan $85.4B AUM 91.09% 1-Year Est. Return

Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return

NewSquare Capital's ANIP Position: Q4 2016 in Review

NewSquare Capital sold out of ANI Pharmaceuticals (ANIP) in Q4 2016, closing a stake of 38 shares — an estimated $3K sold.

NewSquare Capital first reported a position in ANIP in Q3 2016 and held it in 1 quarter. The position peaked at $3K in Q3 2016. 157 funds tracked by Wall St. Rank hold ANIP as of Q4 2016.

NewSquare Capital reported no remaining ANI Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
NewSquare Capital sold 38 ANI Pharmaceuticals shares in Q4 2016, an estimated $3K.
NewSquare Capital first reported a position in ANI Pharmaceuticals in Q3 2016 and held it in 1 quarter.
NewSquare Capital's ANI Pharmaceuticals position peaked at $3K in Q3 2016.
157 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q4 2016.

Based on NewSquare Capital's 13F filing for Q4 2016, filed 1 Feb 2017.